Piroxicam: restriction of indications: labelling change. Only half-measures.
Piroxicam has too many cutaneous and gastrointestinal adverse effects and yet, it remains on the market.
D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D002318:Cardiovascular Diseases / Q000139:chemically induced*; D017277:Drug Approval; D004348:Drug Labeling; D005060:Europe; D005767:Gastrointestinal Diseases / Q000139:chemically induced*; D006801:Humans; D010146:Pain / Q000188:drug therapy; D010894:Piroxicam / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use
D000894:Anti-Inflammatory Agents, Non-Steroidal; D010894:Piroxicam